Seres Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Hello and welcome. My name is [Pasi Kash], and I'm associate at JPMorgan. It's my pleasure to introduce our speaker for today, Eric Shaff, President and CEO of Seres Therapeutics. And with that, I'll hand over to Eric to get us started.
Good morning, everybody, and thanks to JPMorgan for inviting us to present today. We're thrilled to be in person with those in the room as well as those joining us on the phone or online after a couple of years of being virtual, it's terrific to be together. And we think it's a great time to connect with you with the opportunity to talk about Seres and in some sense, what we've accomplished in 2022. But more importantly, what we think about in 2023, and we think that 2023 will be an incredibly important year for series for the microbiome space and really most importantly for patients.
And in any new treatment modality and any new therapeutic modality, there can be hope, there can be the kind of aspiration of treating patients sometime
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |